This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amgen/AstraZeneca's Asthma Drug Misses Phase III Study Goal
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca (AZN) plan to file regulatory applications for tezepelumab next year.
Top Research Reports for Amazon, Walmart & UnitedHealth
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com (AMZN), Walmart (WMT) and UnitedHealth Group (UNH).
Clovis' (CLVS) Rubraca Confirmatory Study Meets Endpoint
by Zacks Equity Research
Clovis' (CLVS) Rubraca achieves significant improvement in progression free survival compared to chemotherapy in late-stage confirmatory study for BRCA-mutated ovarian cancer indication.
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $37.01, marking a -0.88% move from the previous day.
Merck (MRK) Gets FDA's Priority Review for Another Keytruda sBLA
by Zacks Equity Research
The FDA accepts Merck's (MRK) sBLA for Keytruda combo for first-line metastatic esophageal and gastroesophageal junction cancer, under a priority review. The FDA's verdict is awaited on Apr 13, 2021.
TIPS ETFs to Buy for 2021 on Inflation Trade
by Sweta Killa
The COVID-19 vaccines and their availability have raised the prospect of inflation as we move ahead into the next year.
Gilead's (GILD) CAR T Cell Therapy Tecartus Wins EC Nod
by Zacks Equity Research
Gilead (GILD) company, Kite, gets conditional marketing authorization for CAR T cell therapy, Tecartus.
Glaxo's (GSK) Rukobia Gets CHMP Nod for Heavily Pre-Treated HIV
by Zacks Equity Research
Glaxo (GSK) receives positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rukobia for treating HIV-1 infection in heavily pre-treated adult HIV patients.
Merck (MRK) Keytruda Gets CHMP Nod for First-Line Colon Cancer
by Zacks Equity Research
Merck's (MRK) regulatory application seeking label expansion of Keytruda as first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer gets positive CHMP opinion.
Gilead (GILD) to Buy MYR GmbH for EUR1.15 Billion in Cash
by Zacks Equity Research
Gilead (GILD) will purchase MYR GmbH for EUR1.15 billion and add HDV treatment Hepcludex to its portfolio.
Glaxo (GSK)/Sanofi Delay Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
Glaxo (GSK)/Sanofi's (SNY) adjuvanted recombinant COVID-19 vaccine candidate shows low immune response in older adults in phase I/II study. The companies will develop the vaccine with an improved antigen formulation.
Pharma Stock Roundup: FDA Panel's Nod to PFE/BNTX Coronavirus Vaccine, Other Updates
by Kinjel Shah
An FDA panel recommends granting approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. Glaxo (GSK)/Sanofi (SNY) COVID-19 vaccine plan delays.
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $37.97, marking a +0.34% move from the previous day.
Inflation to Pick Up in 2021: Bet on TIPS ETFs
by Sweta Killa
The expectation for an uptick in inflation has led to investors' flocking to Treasury Inflation Protected Securities (TIPS) ETFs.
Emerging Markets Hit Record High: 5 Top-Performing ETFs YTD
by Sweta Killa
While many emerging market ETFs have been performing remarkably well, we highlight five funds that are leading the space from a year-to-date basis.
Glaxo's (GSK) Nucala Filing for Nasal Polyps Accepted by FDA
by Zacks Equity Research
The FDA accepts Glaxo's (GSK) regulatory filing for Nucala to treat patients with chronic rhinosinusitis with nasal polyps. The drug is already approved for three other indications.
Gilead's (GILD) Kite Presents Data on CAR T Cell Therapy at ASH
by Zacks Equity Research
Gilead (GILD) posts positive data on CAR T Cell Therapy Yescarta from multiple studies at ASH.
Pharma Stock Roundup: AZN COVID-19 Vaccine Interim Data, PFE Emergency Use Appeal
by Kinjel Shah
AstraZeneca (AZN) COVID-19 vaccine candidate proves effective in late-stage study. Pfizer (PFE) seeks Emergency use for its COVID-19 vaccine candidate.
The Zacks Analyst Blog Highlights: UnitedHealth, CRM, GSK, Square and American Electric Power
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, CRM, GSK, Square and American Electric Power
Sanofi's (SNY) Meningitis Vaccine MenQuadfi Wins EU Approval
by Zacks Equity Research
The European Commission nods to Sanofi's (SNY) MenQuadfi, a meningococcal vaccine for individuals, aged 12 months and older.
Glaxo's (GSK) RSV Vaccine for Pregnant Women Enters Phase III
by Zacks Equity Research
Glaxo (GSK) is developing vaccine against respiratory syncytial virus for pediatric patients, pregnant women and older adults. The candidates hold significant potential.
Merck (MRK) to Buy OncoImmune, Add Late-Stage COVID-19 Treatment
by Zacks Equity Research
The acquisition of OncoImmune will boost Merck's (MRK) portfolio with CD24Fc, a candidate in phase III studies for the treatment of patients with severe and critical COVID-19.
Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More
by Kinjel Shah
Pfizer (PFE) COVID-19 vaccine candidate proves to be 95% effective in final analysis. Sanofi (SNY), Lilly (LLY), Merck (MRK) & Glaxo (GSK) provide FDA updates.
Top Stock Reports for UnitedHealth, salesforce & GlaxoSmithKline
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), salesforce.com (CRM) and GlaxoSmithKline (GSK).
Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate
by Zacks Equity Research
Gilead (GILD) announces successful top-line results from a phase I/II study on its investigational, long-acting HIV-1 capsid inhibitor.